- Record: found
- Abstract: not found
- Article: not found
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
Selidji T. Agnandji ,
Angela Huttner ,
Madeleine E. Zinser ,
Patricia Njuguna ,
Christine Dahlke ,
José F. Fernandes ,
Sabine Yerly ,
Julie-Anne Dayer ,
Verena Kraehling ,
Rahel Kasonta ,
Akim A. Adegnika ,
Marcus Altfeld ,
Floriane Auderset ,
Emmanuel B. Bache ,
Nadine Biedenkopf ,
Saskia Borregaard ,
Jessica S. Brosnahan ,
Rebekah Burrow ,
Christophe Combescure ,
Jules Desmeules ,
Markus Eickmann ,
Sarah K. Fehling ,
Axel Finckh ,
Ana Rita Goncalves ,
Martin P. Grobusch ,
Jay Hooper ,
Alen Jambrecina ,
Anita L. Kabwende ,
Gürkan Kaya ,
Domtila Kimani ,
Bertrand Lell ,
Barbara Lemaître ,
Ansgar W. Lohse ,
Marguerite Massinga-Loembe ,
Alain Matthey ,
Benjamin Mordmüller ,
Anne Nolting ,
Caroline Ogwang ,
Michael Ramharter ,
Jonas Schmidt-Chanasit ,
Stefan Schmiedel ,
Peter Silvera ,
Felix R. Stahl ,
Henry M. Staines ,
Thomas Strecker ,
Hans C. Stubbe ,
Benjamin Tsofa ,
Sherif Zaki ,
Patricia Fast ,
Vasee Moorthy ,
Laurent Kaiser ,
Sanjeev Krishna ,
Stephan Becker ,
Marie-Paule Kieny ,
Philip Bejon ,
Peter G. Kremsner ,
Marylyn M. Addo ,
Claire-Anne Siegrist
April 28 2016
April 28 2016
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The replication-competent recombinant vesicular stomatitis virus (rVSV)-based vaccine
expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and
immunogenicity testing before its use in West Africa.